Analyst Conference Summaries

Biotechnology Investor Aids

MiNK Therepeutics
INKT

conference date: November 3, 2022 @ 5:30 AM Pacific Time

MiNK Therapeutics a Bargain for Cell Therapies [June 23, 2022 at Seeking Alpha]

2022
Mink
Therapeutics
Q1 2022
Press Release
Mink
Therapeutics
Q2 2022
Mink
Therapeutics
Q3 2022
 
May 10, 2022 Aug. 9, 2022 Nov. 3, 2022  

MiNK Therapeutics (INKT) is a clinical-stage biotechnology company specializing in cell therapies for cancers and immunological diseases.

MiNK Therapeutics web site


Note: Agenus (AGEN) owns a majroity of the shares of INKT common stock, per 2021 10-K

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CDTX
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SANA
 SGEN
 VBLT
 VRTX
 VSTM
 XLRN
 WBA
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2022 William P. Meyers